Themis Medicare Downgraded to Strong Sell Amid Deteriorating Financials and Quality Metrics

Financial Trend Deterioration Triggers Downgrade

The most pronounced factor behind the downgrade is the sharp decline in Themis Medicare’s financial trend. The company’s financial score plummeted from a positive 9 to a negative -14 over the last quarter ending June 2026. This reversal is underscored by a staggering 7,080.2% fall in quarterly PAT, which plunged to a loss of ₹34.65 crores compared to the previous four-quarter average. Operating profitability has also collapsed, with PBDIT registering a negative ₹52.42 crores and operating profit to net sales ratio dropping to a distressing -60.28%.

Interest expenses have surged to ₹2.98 crores, while operating profit to interest coverage ratio has deteriorated to -17.59 times, indicating the company’s earnings are insufficient to cover interest obligations. Cash and cash equivalents have dwindled to ₹9.15 crores at half-year end, and the debtors turnover ratio has fallen to 1.92 times, signalling potential liquidity and collection challenges. These metrics collectively paint a picture of financial stress and weakening operational efficiency.

Despite a quarterly EPS peak of ₹2.67, the overall financial health is compromised by negative EBITDA of ₹-41.97 crores and a PBT less other income of ₹-55.34 crores. The company’s weak financial footing is further reflected in its micro-cap market capitalisation and volatile stock returns, which have underperformed the Sensex over medium to long-term horizons.

Quality Grade Slips to Below Average

Themis Medicare’s quality grade has been downgraded from average to below average, reflecting deteriorating fundamentals over the past five years. Sales growth has been modest at 2.39% annually, but EBIT growth has plunged dramatically by -194.65%, signalling operational challenges. The company’s average EBIT to interest coverage ratio stands at a low 2.84, while debt to EBITDA ratio is elevated at 10.13, indicating high leverage and financial risk.

Net debt to equity remains moderate at 0.20, but sales to capital employed ratio is weak at 0.86, suggesting inefficient use of capital. The tax ratio is 26.76%, and dividend payout ratio is low at 15.43%, reflecting limited returns to shareholders. A significant concern is the high promoter share pledge of 43.39%, which has increased by 40.96% in the last quarter, adding pressure on stock price in volatile markets.

Institutional holding is negligible at 0.02%, indicating limited confidence from large investors. Return on capital employed (ROCE) and return on equity (ROE) average at 11.55% and 12.31% respectively, which are below industry averages, further justifying the downgrade in quality assessment.

Technical Indicators Show Mixed Signals but Trend Weakens

Technically, Themis Medicare’s trend has shifted from bullish to mildly bullish, reflecting a cautious outlook. Weekly MACD remains bullish, but monthly MACD is only mildly bullish. RSI on both weekly and monthly charts shows no clear signal, while Bollinger Bands indicate mild bullishness weekly but bearishness monthly. Daily moving averages suggest mild bullish momentum, yet the KST indicator is bullish weekly and mildly bullish monthly.

Contrastingly, Dow Theory signals are mildly bearish weekly but mildly bullish monthly, and On-Balance Volume (OBV) is mildly bearish weekly while bullish monthly. This mixed technical picture suggests short-term volatility and uncertainty, which combined with weak fundamentals, supports the Strong Sell rating.

Stock Performance and Market Context

Themis Medicare’s stock price closed at ₹104.70 on 17 Aug 2026, up 0.67% from the previous close of ₹104.00. The 52-week price range is ₹65.00 to ₹147.99, indicating significant volatility. Recent returns have lagged the Sensex benchmark, with a one-month return of -10.32% versus Sensex’s +1.24%, and a three-year return of -36.58% compared to Sensex’s +19.28%. Even over five and ten years, the stock has underperformed the broader market, with returns of -7.74% and +104.17% respectively, against Sensex’s +40.72% and +177.10%.

This underperformance, coupled with deteriorating financials and quality metrics, highlights the elevated risk profile of Themis Medicare for investors seeking stable pharmaceutical sector exposure.

Long-Term Risks and Outlook

Themis Medicare’s downgrade to Strong Sell is primarily driven by its weak long-term fundamental strength. The company’s operating losses and negative EBITDA highlight ongoing operational inefficiencies. The substantial promoter share pledge increases the risk of forced selling in adverse market conditions, potentially exacerbating price declines.

With cash reserves at a low ₹9.15 crores and interest costs rising, liquidity constraints may intensify. The company’s inability to generate consistent profits despite a recent EPS high of ₹2.67 raises concerns about sustainable earnings growth. Investors should be wary of the stock’s elevated risk profile, especially given its underperformance relative to the Sensex and sector peers.

In summary, Themis Medicare Ltd’s downgrade reflects a comprehensive reassessment of its financial health, quality metrics, and technical outlook. The Strong Sell rating signals caution for investors, suggesting that alternative pharmaceutical stocks with stronger fundamentals and technicals may offer better risk-adjusted returns.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today